Investigational drug · Phase 2
Relmacabtagene Autoleucel
Also called: JWCAR029
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma.
Phase 2Last checked: Nov 20, 2026Latest source record: Feb 11, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
21
Any phase or sponsor naming "Relmacabtagene Autoleucel"
First trial start
2023
Nov 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Relmacabtagene Autoleucel", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Lymphoma, Large B-Cell, Diffuse
- Follicular Lymphoma Grade 3B
- High-grade B-cell Lymphoma
- Mediastinal B-Cell Diffuse Large Cell Lymphoma
Approved drugs for the same conditions: Lymphoma (non-Hodgkin) · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Relmacabtagene Autoleucel" as an intervention, largest first.
- Relmacabtagene Autoleucel in Patients With LBCLStatus unknown
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT06142175 · 200 participants (planned) · Start Dec 28, 2022 · Primary completion Dec 31, 2024
Drug: Relmacabtagene Autoleucel · For: Large B-cell Lymphoma
Sites: Shanghai, China
- Relmacabtagene Autoleucel in Hematologic MalignanciesNot yet recruiting
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT06142188 · 150 participants (planned) · Start Dec 28, 2023 · Primary completion Dec 31, 2038
Drug: Relmacabtagene Autoleucel · For: Lymphoma, B-Cell; Large B-cell Lymphoma; Follicular Lymphoma
Sites: Beijing, China · 2 sites in all
- Chidamide Bridging for CAR-T TherapyPivotal-lookingStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT05370547 · 120 participants (planned) · Start May 25, 2022 · Primary completion Jun 30, 2024
Drug: Chidamide; Fludarabine and cyclophosphamide and 1 more · For: Non Hodgkin's Lymphoma
Sites: Beijing, China; Guangzhou, China; Wuhan, China · 13 sites in all
- Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHLActive, not recruiting
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT06093841 · 46 participants (planned) · Start Nov 3, 2023 · Primary completion Jan 21, 2024
Drug: Relmacabtagene Autoleucel; Fludarabine and 1 more · For: Lymphoma, Large B-Cell, Diffuse; Follicular Lymphoma Grade 3B; High-grade B-cell Lymphoma and 1 more
Sites: Guangzhou, China; Zhengzhou, China; Changsha, China · 13 sites in all
Ruijin HospitalAcademic, hospital or other
NCT06876688 · 30 participants (planned) · Start Nov 30, 2023 · Primary completion Nov 30, 2028
Drug: Relma-cel Followed by Tislelizumab · For: CNS Lymphoma
Sites: Beijing, China; Guangzhou, China; Henan, China · 6 sites in all
- Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07077512 · 30 participants (planned) · Start Sep 15, 2025 · Primary completion Jan 15, 2027
Drug: Autoleucel (Relmacabtagene Autoleucel); Sintilimab (PD-1 inhibitor) · For: Large B Cell Diffuse Lymphoma; Mantle Cell Lymphoma (MCL); Follicular Lymphoma ( FL)
Sites: Guangzhou, China · 3 sites in all
Zhengzhou UniversityAcademic, hospital or other
NCT07198464 · 30 participants (planned) · Start Oct 7, 2025 · Primary completion Oct 1, 2029
Drug: Relmacabtagene autoleucel and transplantation · For: Primary Central Nervous System Lymphoma (PCNSL)
- Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T TherapiesActive, not recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyAcademic, hospital or other
NCT06220097 · 28 participants (planned) · Start Feb 1, 2022 · Primary completion Aug 1, 2024
Drug: Mitoxantrone hydrochloride liposome Injection-based bridging therapy+ Fludarabine-based chemotherapy +CD19 CAR-T Cells · For: B-cell Acute Lymphoblastic Leukemia; B-cell Lymphoma Refractory
Sites: Wuhan, China
Shanghai Ming Ju Biotechnology Co., Ltd.Industry
NCT05765006 · 24 participants (planned) · Start Feb 24, 2023 · Primary completion Dec 30, 2024
Drug: Relma-cel · For: Systemic Lupus Erythematosus
Sites: Shanghai, China
- Glofitamab Combined With CAR-T Therapy in R/R DLBCLNot yet recruiting
Ruijin HospitalAcademic, hospital or other
NCT07326371 · 24 participants (planned) · Start Mar 2026 · Primary completion Jul 2027
Drug: Glofitamab; Obinutuzumab and 2 more · For: DLBCL - Diffuse Large B Cell Lymphoma
Newest research
PubMed records naming it or its code names, newest first.
- Phase 2 study of relmacabtagene autoleucel (CD19 CAR-T) for relapsed/refractory mantle cell lymphoma in Chinese adults.
Xie Y, Zhou KS, Li LF, et al. · Blood Adv 2026
- Cost-Effectiveness of Chimeric Antigen Receptor (CAR) T-Cell Therapy for Blood Cancers: An Updated Systematic Review.
Patel N, Farid S, Gomes M · Pharmacoecon Open 2026
- Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with moderately to severely active systemic lupus erythematosus: a phase I dose-escalation study.
Wang Y, Yang S, Yu Y, et al. · J Autoimmun 2025
- Clinical outcome and immunophenotype of axicabtagene ciloleucel (axi-cel) and relmacabtagene autoleucel (relma-cel) in relapsed/refractory large B-Cell lymphoma on Chinese population: a single-center experience.
Zhao D, Ruan J, Wei C, et al. · Ann Hematol 2025
- Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study.
Song Y, Zou D, Yang H, et al. · Br J Haematol 2025
- Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial.
Shu J, Xie W, Mei C, et al. · EClinicalMedicine 2025
Also in development for Lymphoma, Large B-Cell, Diffuse
- MK-2140Zilovertamab Vedotin, VLS-101Phase 39 trials
Merck & Co. · Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, B-cell Acute Lymphoblastic Leukemia
- MK-1045CN-201Phase 36 trials
Merck & Co. · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, Follicular
- JNJ-90014496Phase 21 trial
Johnson & Johnson (Janssen) · Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.